Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dental, and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-ku, Okayama 700-8530 Japan.
Adv Drug Deliv Rev. 2014 Jul;74:2-11. doi: 10.1016/j.addr.2013.08.010. Epub 2013 Aug 30.
Though much progress has been made in the development of anti-tumor chemotherapeutic agents, refractoriness is still a major clinical difficulty because little is known about the non-autonomous mechanisms involved. Abnormal capillary structures in tumors, for example, are well documented, but a thorough characterization of microcirculation, including functional consequences with particular regard to drug delivery and intratumor accumulation, is still required for many kinds of tumor. In this review, we highlight how use of synthesized nanoparticles, themselves a product of emerging nanotechnology, are beginning to open up new perspectives in understanding the functional and therapeutic consequences of capillary structure within tumors. Furthermore, nanoparticles promise exciting new clinical applications. I also stress the urgent necessity of developing clinically relevant tumor models, both in vivo and in vitro.
尽管在抗肿瘤化学疗法药物的开发方面已经取得了很大进展，但耐药性仍然是一个主要的临床难题，因为人们对涉及的非自主机制知之甚少。例如，肿瘤中异常的毛细血管结构已有充分的记录，但对于许多类型的肿瘤，仍然需要对微循环进行彻底的特征描述，包括与药物输送和肿瘤内积累有关的功能后果。在这篇综述中，我们强调了如何利用合成纳米粒子（新兴纳米技术的产物）开始为理解肿瘤内毛细血管结构的功能和治疗后果开辟新的视角。此外，纳米粒子有望带来令人兴奋的新的临床应用。我还强调了迫切需要开发临床相关的肿瘤模型，包括体内和体外模型。
